American Association for Cancer Research
21598290cd160178-sup-162212_1_supp_3485174_h6wyyh.xlsx (7.21 MB)

Supplementary Table S2 from CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions

Download (7.21 MB)
posted on 2023-04-03, 21:05 authored by Diana M. Munoz, Pamela J. Cassiani, Li Li, Eric Billy, Joshua M. Korn, Michael D. Jones, Javad Golji, David A. Ruddy, Kristine Yu, Gregory McAllister, Antoine DeWeck, Dorothee Abramowski, Jessica Wan, Matthew D. Shirley, Sarah Y. Neshat, Daniel Rakiec, Rosalie de Beaumont, Odile Weber, Audrey Kauffmann, E. Robert McDonald, Nicholas Keen, Francesco Hofmann, William R. Sellers, Tobias Schmelzle, Frank Stegmeier, Michael R. Schlabach

Annotations for the sgRNA libraries containing sequences, target gene information, Zscore and RNAseq data for each cell line screened.



CRISPR/Cas9 has emerged as a powerful new tool to systematically probe gene function. We compared the performance of CRISPR to RNAi-based loss-of-function screens for the identification of cancer dependencies across multiple cancer cell lines. CRISPR dropout screens consistently identified more lethal genes than RNAi, implying that the identification of many cellular dependencies may require full gene inactivation. However, in two aneuploid cancer models, we found that all genes within highly amplified regions, including nonexpressed genes, scored as lethal by CRISPR, revealing an unanticipated class of false-positive hits. In addition, using a CRISPR tiling screen, we found that sgRNAs targeting essential domains generate the strongest lethality phenotypes and thus provide a strategy to rapidly define the protein domains required for cancer dependence. Collectively, these findings not only demonstrate the utility of CRISPR screens in the identification of cancer-essential genes, but also reveal the need to carefully control for false-positive results in chromosomally unstable cancer lines.Significance: We show in this study that CRISPR-based screens have a significantly lower false-negative rate compared with RNAi-based screens, but have specific liabilities particularly in the interrogation of regions of genome amplification. Therefore, this study provides critical insights for applying CRISPR-based screens toward the systematic identification of new cancer targets. Cancer Discov; 6(8); 900–13. ©2016 AACR.See related commentary by Sheel and Xue, p. 824.See related article by Aguirre et al., p. 914.This article is highlighted in the In This Issue feature, p. 803

Usage metrics

    Cancer Discovery



    Ref. manager